Our Promise

CardiaPill® is our lead product.

David Bell, M.D.

Professor of Medicine at the University of Alabama at Birmingham, School of Medicine
Dr. Bell is a leading authority on the prevention and treatment of type 2 diabetes. During his distinguished career, he has contributed more than 180 articles to the medical literature. He is an active researcher and has served as Director of the Endocrine Clinical Research Program at the University of Alabama Birmingham.

 

Dr. Bell speaks nationally and internationally on the treatment of type 2 diabetes and its complications, and he is currently a member of the editorial boards of Endocrine Practice, Treatments in Endocrinology, Diabetes, and Obesity and Metabolism. He is a recipient of the Distinguished Clinician Award from the American College of Endocrinology for outstanding contribution as a master educator and clinician. Currently he is an investigator in the DREAM trials.

DREAM is an international, multi-center, randomized, double-blinded, placebo-controlled trial involving 4,000 participants at high risk for developing type II diabetes mellitus. Participants receive Ramipril (ACE-Inhibitor) or placebo and Rosiglitazone (a drug used to lower glucose in the blood) or placebo (One of the goals of the study is to establish epidemiological associations between cardiovascular disease and type II diabetes mellitus).